Replimune (REPL) Announces $125M Proposed Public Offering of Common Stock, Warrants

Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced a proposed public offering of $125 million of shares of its common stock and pre-funded warrants to purchase shares of common stock. All securities in the offering will be offered by Replimune. In addition, Replimune intends to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock from Replimune at the public offering price, less the underwriting discounts and commissions.

J.P. Morgan Securities LLC and SVB Securities LLC are acting as joint book-running managers for the proposed offering. The proposed offering is subject to market and other customary closing conditions, and Replimune cannot assure you as to whether or when the proposed offering may be completed.

You May Also Be Interested In

• Huang Calls AI 'the Great Equalizer' During G20 Event
• Black Titan converts $1.5M note into 2.9M shares
• Advent International proposes $1.02-per-share buyout of Definitive Healthcare